MX2022015586A - Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70. - Google Patents

Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.

Info

Publication number
MX2022015586A
MX2022015586A MX2022015586A MX2022015586A MX2022015586A MX 2022015586 A MX2022015586 A MX 2022015586A MX 2022015586 A MX2022015586 A MX 2022015586A MX 2022015586 A MX2022015586 A MX 2022015586A MX 2022015586 A MX2022015586 A MX 2022015586A
Authority
MX
Mexico
Prior art keywords
genetically modified
natural killer
killer cells
modified natural
car
Prior art date
Application number
MX2022015586A
Other languages
English (en)
Inventor
Chao Guo
Ivan Chan
Alexandra Leida Liana Lazetic
James Barnaby Trager
Katherine Jamboretz
Original Assignee
Nkarta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nkarta Inc filed Critical Nkarta Inc
Publication of MX2022015586A publication Critical patent/MX2022015586A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/464438—Tumor necrosis factors [TNF], CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/56—Kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Varias modalidades de los métodos y composiciones divulgados en la presente se refieren a células inmunitarias que se modifican para expresar receptores de antígeno quimérico (CAR) y/o modificados genéticamente para reducir los posibles efectos secundarios de la inmunoterapia celular. Varias modalidades se refieren a modificaciones genéticas a las células inmunitarias, tal como linfocitos citolíticos naturales (NK), para reducir, sustancialmente, reducir, o eliminar la expresión de un marcador por las células inmunitarias que de otra manera provocarían que se autodirigieran por el CAR. En varias modalidades, el CAR se dirige a CD70, y en algunas modalidades se usa para inmunoterapia de carcinoma de células renales.
MX2022015586A 2020-06-12 2021-06-10 Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70. MX2022015586A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063038645P 2020-06-12 2020-06-12
US202063090041P 2020-10-09 2020-10-09
US202163141411P 2021-01-25 2021-01-25
US202163201490P 2021-04-30 2021-04-30
PCT/US2021/036879 WO2021252804A1 (en) 2020-06-12 2021-06-10 Genetically modified natural killer cells for cd70-directed cancer immunotherapy

Publications (1)

Publication Number Publication Date
MX2022015586A true MX2022015586A (es) 2023-03-15

Family

ID=78846545

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015586A MX2022015586A (es) 2020-06-12 2021-06-10 Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.

Country Status (10)

Country Link
US (1) US12012458B2 (es)
EP (1) EP4165171A1 (es)
JP (1) JP2023530408A (es)
KR (1) KR20230024984A (es)
AU (1) AU2021286655A1 (es)
BR (1) BR112022025295A2 (es)
CA (1) CA3184752A1 (es)
IL (1) IL298510A (es)
MX (1) MX2022015586A (es)
WO (1) WO2021252804A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4165171A1 (en) 2020-06-12 2023-04-19 Nkarta, Inc. Genetically modified natural killer cells for cd70-directed cancer immunotherapy
AU2021377699A1 (en) * 2020-11-13 2023-06-15 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
JP2023552998A (ja) * 2020-12-03 2023-12-20 ンカルタ・インコーポレイテッド 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021401052A1 (en) 2020-12-18 2023-06-22 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
EP4277638A1 (en) * 2021-01-12 2023-11-22 Hadasit Medical Research Services&Development Ltd. Improved adoptive cell transfer therapy for cancer
WO2023172879A2 (en) * 2022-03-07 2023-09-14 Nkarta, Inc. Multiplex gene edited cells for cd70-directed cancer immunotherapy
CN115925923B (zh) * 2022-09-26 2023-09-15 吉林大学 一种催化Aβ42寡聚体降解的单链抗体、单链抗体基因及其应用
CN116445416B (zh) * 2023-06-08 2023-10-17 山东兴瑞生物科技有限公司 一种基因修饰的car-nk细胞及其制备方法和应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022311A1 (en) 1996-05-21 2003-01-30 Dunnington Damien D. Human CIS protein
US6323317B1 (en) 1996-11-01 2001-11-27 The Walter And Eliza Hall Institute Of Medical Research Therapeutic and diagnostics proteins comprising a SOCS box
WO2003085093A2 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
AU2005330703A1 (en) 2004-07-19 2006-10-26 Baylor College Of Medicine Modulation of cytokine signaling regulators and applications for immunotherapy
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US7868159B2 (en) 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
EP1940460A4 (en) 2005-10-27 2009-08-12 Biogen Idec Inc OLIGOD DRO CYTEN MYELIN GLYCOPROTEIN COMPOSITIONS AND USES THEREOF
EP2035454A2 (en) * 2006-05-19 2009-03-18 Amgen, Inc. Antibodies to sars coronavirus
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
US20120192298A1 (en) 2009-07-24 2012-07-26 Sigma Aldrich Co. Llc Method for genome editing
WO2012078540A1 (en) 2010-12-08 2012-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulating immune cell activity using cytokine-induced src homology 2 and/or high temperature requirement a-1
PT3613439T (pt) 2013-02-15 2021-05-12 Univ California Recetor de antigénio quimérico e métodos de utilização do mesmo
CN111057151B (zh) * 2014-01-06 2022-05-03 豪夫迈·罗氏有限公司 单价血脑屏障穿梭模块
RU2714258C2 (ru) * 2014-02-14 2020-02-13 Селлектис Клетки для иммунотерапии, сконструированные для нацеливания на антиген, присутствующий одновременно на иммунных клетках и на патологических клетках
CN106103475B (zh) 2014-03-11 2021-01-12 塞勒克提斯公司 产生同种异体移植相容的t细胞的方法
EP3143134B1 (en) * 2014-05-15 2020-10-28 National University of Singapore Modified natural killer cells and uses thereof
WO2015187521A2 (en) * 2014-06-03 2015-12-10 Merck Sharp & Dohme Corp. Anti-blys antibodies
KR102656470B1 (ko) 2014-12-10 2024-04-09 리전츠 오브 더 유니버스티 오브 미네소타 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기
EP3256494A4 (en) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
US10100118B2 (en) * 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
US10358497B2 (en) * 2015-09-29 2019-07-23 Amgen Inc. Methods of treating cardiovascular disease with an ASGR inhibitor
CN109312340A (zh) 2016-03-04 2019-02-05 爱迪塔斯医药公司 用于癌症免疫疗法的crispr-cpf1相关方法、组合物和组分
EP3519443A4 (en) 2016-09-30 2020-06-10 Baylor College of Medicine CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE
JP2019536447A (ja) 2016-10-27 2019-12-19 インティマ バイオサイエンス， インコーポレイテッド Ｔ細胞療法のウイルス法
WO2018098363A2 (en) * 2016-11-23 2018-05-31 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
US20180100016A1 (en) 2016-12-22 2018-04-12 Xiaotong Song Use of car-modified human natural killer cells to treat cancer
US11634486B2 (en) * 2016-12-23 2023-04-25 Bluefin Biomedicine, Inc. Anti-SEZ6L2 antibodies and antibody drug conjugates
EP3562492A4 (en) 2016-12-30 2020-12-09 Celularity, Inc. GENETICALLY MODIFIED NATURAL KILLER CELLS
SG11201908492PA (en) 2017-03-27 2019-10-30 Nat Univ Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
BR112019025667A2 (pt) * 2017-06-05 2020-09-01 Mie University proteína de ligação ao antígeno que reconhece o peptídeo derivado de mage-a4
WO2018231759A1 (en) * 2017-06-12 2018-12-20 Obsidian Therapeutics, Inc. Pde5 compositions and methods for immunotherapy
WO2019006418A2 (en) * 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
CA3093078A1 (en) 2018-03-06 2019-09-12 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
CN110351878B (zh) * 2018-04-04 2023-07-14 华为技术有限公司 一种随机接入处理方法和相关设备
US20200063100A1 (en) 2018-05-11 2020-02-27 Crispr Therapeutics Ag Methods and compositions for treating cancer
CN112654363A (zh) 2018-07-09 2021-04-13 瑟罗泽恩公司 组织特异性wnt信号增强分子和其用途
CA3140393A1 (en) 2019-06-04 2020-12-10 Nkarta, Inc. Combinations of engineered natural killer cells and engineered t cells for immunotherapy
KR20220026586A (ko) 2019-06-27 2022-03-04 크리스퍼 테라퓨틱스 아게 암 치료를 위한 키메라 항원 수용체 t세포 및 nk세포 억제제의 용도
JP2022547865A (ja) 2019-09-06 2022-11-16 クリスパー セラピューティクス アクチェンゲゼルシャフト 培養液中における改善された残存率を有する遺伝子操作されたｔ細胞
JP2023501602A (ja) 2019-11-13 2023-01-18 クリスパー セラピューティクス アクチェンゲゼルシャフト Ｃｄ７０を標的化する遺伝子操作されたｔ細胞を使用する腎細胞癌（ｒｃｃ）療法
AU2020384951A1 (en) 2019-11-13 2022-05-19 Crispr Therapeutics Ag Therapy for hematopoietic cell malignancies using genetically engineered T cells targeting CD70
AR120470A1 (es) 2019-11-13 2022-02-16 Crispr Therapeutics Ag Métodos para fabricar células t car
KR20220119038A (ko) 2019-11-25 2022-08-26 케이에스큐 세러퓨틱스 인코포레이티드 종양 침윤 림프구의 활성화 및 확장을 위한 방법
US20230084099A1 (en) 2020-02-03 2023-03-16 National University Corporation Tokai National Higher Education And Research System Anti-meflin antibody for use in treatment of cancer in subject having cancer, and pharmaceutical composition comprising the antibody
JP2023526282A (ja) * 2020-05-13 2023-06-21 ボナム セラピューティクス，インク． タンパク質複合体の組成物及びその使用方法
EP4165171A1 (en) 2020-06-12 2023-04-19 Nkarta, Inc. Genetically modified natural killer cells for cd70-directed cancer immunotherapy
KR20230041819A (ko) 2020-07-29 2023-03-24 얀센 바이오테크 인코포레이티드 Hla-g 항원-결합 도메인을 포함하는 단백질 및 이의 용도
KR20230074515A (ko) 2020-09-23 2023-05-30 크리스퍼 테라퓨틱스 아게 개선된 기능성 및 지속성을 갖는 붕괴된 레그나제-1 및/또는 tgfbrii를 지니는 유전자 조작된 t 세포
WO2022238963A2 (en) 2021-05-12 2022-11-17 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating solid tumors
AR125851A1 (es) 2021-05-12 2023-08-16 Crispr Therapeutics Ag Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en el tratamiento de neoplasias malignas hematopoyéticas
WO2023172879A2 (en) 2022-03-07 2023-09-14 Nkarta, Inc. Multiplex gene edited cells for cd70-directed cancer immunotherapy

Also Published As

Publication number Publication date
US20220002424A1 (en) 2022-01-06
JP2023530408A (ja) 2023-07-18
EP4165171A1 (en) 2023-04-19
AU2021286655A1 (en) 2023-01-05
WO2021252804A1 (en) 2021-12-16
CA3184752A1 (en) 2021-12-16
IL298510A (en) 2023-01-01
KR20230024984A (ko) 2023-02-21
BR112022025295A2 (pt) 2023-04-25
US12012458B2 (en) 2024-06-18

Similar Documents

Publication Publication Date Title
MX2022015586A (es) Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.
CR20200571A (es) Moléculas de únion contra bcma y usos de las mismas
MX2021010670A (es) Receptores de antigeno quimerico dirigidos a cd19 y usos de los mismos en inmunoterapia.
WO2023172879A3 (en) Multiplex gene edited cells for cd70-directed cancer immunotherapy
MX2019011514A (es) Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales.
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
WO2020092854A3 (en) Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
MX2019008503A (es) Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos.
MX2020007281A (es) Composiciones y métodos que se dirigen a cánceres que expresan cd99.
MX2020007338A (es) Composiciones y métodos para el direccionamiento a tipos de cáncer que expresan clec12a.
MX2022005815A (es) Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70.
MX2020009463A (es) Receptor de antígeno quimérico de receptor de il-13 alfa 2 (il13ra2) para inmunoterapia de células t específica para tumor.
MX2020000686A (es) Composiciones y métodos para el direccionamiento de cánceres que expresan cd33.
MX2022005821A (es) Terapia del carcinoma de celulas renales (rcc) usando linfocitos t modificados por ingenieria genetica dirigidos a cd70.
MX2022015062A (es) Nuevas construcciones para receptores de antígenos quiméricos.
PH12020500632A1 (en) Cd83-binding chimerix antigen receptors
MX2021013368A (es) Celulas t del receptor de antigenos quimericos focalizadas a cd19 especificas del antigeno.
MX2021009967A (es) Metodos para producir celulas t autologas utiles para tratar cancer y composiciones de las mismas.
MX2021012003A (es) Anticuerpos multiespecificos contra antigeno de cancer de la bomba de eflujo y composiciones, reactivos, kits y metodos relacionados con los mismos.
MX2022007107A (es) Composiciones celulares terapeuticas y metodos de preparacion y usos de las mismas.
MX2022005816A (es) Terapia de tumores solidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70.
WO2022120370A3 (en) Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapy
WO2022115641A3 (en) Antigen specific t cells and methods of making and using same
MX2023009581A (es) Composiciones y metodos para tratar tipos de cancer her2 positivos.
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof